

To whom it may concern,

August 20, 2026

Company name: ExaWizards Inc.
Name of representative: Makoto Haruta,
Representative Director and President, CEO
(TSE Code No.4259)
Inquiries: Tomoaki Maekawa,
Executive Officer, Corporate Management
Division Manager, CFO

**Notice Regarding the Start of the SAKIGAKE Consultation for
a Subsidiary's AI-powered Cognitive Function Diagnostic Support App (SaMD)**

ExaWizards Inc. (hereinafter, "the Company") announces that the application for the SAKIGAKE Comprehensive Evaluation Consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) was accepted on August 20, 2026, for the AI-powered Cognitive Function Diagnostic Support App (SaMD) (the "Product") under development by ExaMD, Inc. ("ExaMD"), a wholly owned subsidiary of the Company, and that the consultation will begin.

The Product is a Software as a Medical Device (SaMD) that analyzes cognitive function from voice data collected through smartphones and other devices. It is intended for use not only in medical institutions but also at home. On February 7, 2025, the Product was designated for priority review under the designation system for innovative SaMD. Regarding the clinical trial described in the "Notice Regarding Clinical Trial Notification Submission by Subsidiary for AI-Powered Cognitive Function Diagnostic Support Application (SaMD)" disclosed on February 5, 2026, observation of all planned cases in the trial has been completed by August 2026, and database lock and statistical analysis are currently underway. With the start of the SAKIGAKE Comprehensive Evaluation Consultation, the Company will further accelerate preparations for the marketing approval application and the acquisition of approval.

1. Outline of the Subsidiary

- | | |
|------------------------------------|--|
| (1) Name | ExaMD Inc. |
| (2) Location | 4-2-8 Shibaura, Minato-ku, Tokyo |
| (3) Title & Name of Representative | Representative Director, Koji Hazama |
| (4) Business Description | Planning, development, sales, and alliances (including software as a medical device) of products and services utilizing multimodal AI technology, with the aim of solving social issues related to health and medical themes such as dementia. |
| (5) Capital | 50 million yen |

2. Overview of the SAKIGAKE Comprehensive Evaluation Consultation

The SAKIGAKE Comprehensive Evaluation Consultation is a consultation program designed to enable a smooth and prompt priority review after filing by obtaining PMDA's evaluation of clinical, non-clinical, QMS, reliability, and other aspects in advance of the marketing approval application.

Through this consultation, ExaMD will confirm and organize with PMDA in advance the content of documents required for the approval application and key points of evaluation, aiming to streamline the review process and shorten the review period after filing.

3. Significance of This Milestone and Future Plans

The start of the SAKIGAKE Comprehensive Evaluation Consultation marks an important step in the roadmap toward obtaining marketing approval for the Product. In parallel with the consultation, ExaMD will promptly proceed with database lock and statistical analysis of the clinical trial and, leveraging the benefits of the priority review designation to the fullest, aims to obtain marketing approval within fiscal year 2026 (ending March 31, 2027) and launch the Product at an early date.

4. Impact on Consolidated Results

The impact of this matter on the Company's consolidated financial results for the fiscal year ending March 31, 2027 is minor, and there is no revision to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2027. The impact on subsequent fiscal years is currently under review, and the Company will promptly disclose any matters requiring disclosure as they arise.